Market Overview

UPDATE: J.P. Morgan Initiates Quintiles Transnational at Overweight on Global Market Leader Position

3 Key Questions For Quintiles Transnational Investors Ahead Of M&A
Quintiles Launches Continuous Glucose Monitoring Services To Enhance Diabetes Outcomes
Quintiles Transnational Holdings (Q) Thomas H. Pike on Q2 2016 Results - Earnings Call Transcript (Seeking Alpha)

In a report published Tuesday, J.P. Morgan analyst Tycho W. Peterson initiated coverage on Quintiles Transnational (NYSE: Q) with an Overweight rating and $50.00 price target.

In the report, J.P. Morgan noted, “We are initiating coverage on Quintiles (Q) with an Overweight rating and December 2014 DCF-derived price target of $50. As the global leader in the clinical CRO market, Quintiles sits at the nexus of several important trends, including a continued push toward outsourcing, and the drive by biopharma customers to send more work through fewer, higher-quality CROs. Underlying the dynamic are improving industry trends, including stable biopharma R&D budgets and an increased reliance on outsourcing. We expect Quintiles to outgrow industry peers aided by a diversified global footprint and unique service offerings, and strong cash flow should fund deleveraging, resulting in ~15% EPS CAGR for the next several years.”

Quintiles Transnational closed on Monday at $43.53.

Latest Ratings for Q

May 2016Wells FargoDowngradesOutperformMarket Perform
May 2016CitigroupDowngradesBuyNeutral
May 2016BairdDowngradesOutperformNeutral

View More Analyst Ratings for Q
View the Latest Analyst Ratings

Posted-In: J.P. Morgan Tycho W. PetersonAnalyst Color Initiation Analyst Ratings


Related Articles (Q)

View Comments and Join the Discussion!